Protagenic Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative neuropeptide therapies, has announced the appointment of Bill Nichols Jr. as its new President. This leadership change is part of the company’s strategic initiative to enhance focus on its lead therapeutic candidate, PT00114, which targets stress-related neuropsychiatric disorders.
PT00114 is a novel neuro-active peptide that aims to address the teneurin C-terminal associated peptide (TCAP) pathway, presenting a groundbreaking approach for treating conditions such as anxiety, PTSD, and treatment-resistant depression. By focusing on the biological origins of these disorders, PT00114 seeks to improve treatment effectiveness beyond merely managing symptoms.
With over two decades of experience in various leadership roles across the pharmaceutical sector, Nichols brings substantial expertise in strategy and commercial operations to Protagenic. His previous positions include senior roles at bluebird bio, Dova Pharmaceuticals, and Bristol-Myers Squibb, where he was instrumental in several successful product launches. As President, Nichols will steer corporate strategy and integrated clinical development as the company prepares for Phase 2 clinical trials for PT00114.
In addition to the appointment of Nichols, Protagenic is optimizing its management structure to better align with its focus on PT00114. Alexander Arrow, who has served as Chief Financial Officer since 2016, will transition from his role, though he will remain with the company to ensure a smooth transition. The decision reflects the company’s current size and growth stage, where a new CFO is not deemed necessary at this time.
This leadership transition positions Protagenic to make significant advancements in the clinical development of PT00114, following promising Phase 1 safety and tolerability data released in December 2025. The company plans to initiate Phase 2 enrollment in 2026, with expectations of meaningful clinical outcomes that could lead to improved patient care in the neuropsychiatric space.
Bill Nichols Jr. has been appointed as President of Protagenic Therapeutics, bringing over two decades of leadership experience in biopharmaceuticals. His role will focus on advancing the company's lead candidate, PT00114, and enhancing corporate strategy, positioning the company for significant clinical advancement.
PT00114 is a first-in-class investigational neuropeptide targeting the teneurin C-terminal associated peptide (TCAP) pathway. It is designed to address stress-related neuropsychiatric disorders such as anxiety, PTSD, and treatment-resistant depression, potentially transforming treatment by targeting the biological roots of these conditions.
Protagenic has successfully completed Phase 1 trials for PT00114, demonstrating positive safety and tolerability data. The company is now gearing up to initiate Phase 2 enrolment in 2026, indicating a strong progression towards potential market readiness.
With his extensive background in neuroscience and commercial operations, Bill Nichols is expected to bring valuable insights into clinical development and market access, crucial for driving the successful advancement of PT00114 and potentially unlocking long-term value for both patients and shareholders.
Protagenic has streamlined its leadership team to enhance focus on PT00114's development. This includes the strategic transition of Alexander Arrow from CFO to facilitate a focused management approach, aimed at optimizing resources and effectiveness as the company advances its clinical pipeline.
The TCAP pathway represents a novel mechanism for addressing stress-related neuropsychiatric disorders by targeting the underlying biological causes rather than merely alleviating symptoms. This innovative approach could significantly improve treatment outcomes for conditions that currently have substantial unmet needs.
Protagenic plans to advance PT00114 into Phase 2 clinical studies in 2026, following encouraging safety outcomes from Phase 1 trials. This step is vital for further validating the therapy's efficacy and moving closer to potential commercialisation.
The appointment of Bill Nichols Jr. is a strategic move aimed at accelerating the development of PT00114, which may enhance shareholder confidence and long-term value creation by providing experienced leadership during a critical growth stage for the company.